MUC4 and idiopathic pulmonary fibrosis: This suggests that MUC4 inhibition could be a feasible option to attenuate pulmonary artery remodelling and consequently reduce the PH development associated with IPF, thus avoiding the unsatisfactory results obtained previously using vasodilation agents such as endothelin-1 receptor antagonists [153,154,155].